Menu Search
Equities

Oncoinvent ASA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0RU5:LSE

Oncoinvent ASA

Actions
  • Price (NOK)42.28
  • Today's Change42.28 / --
  • Shares traded14.00
  • 1 Year change-91.51%
  • Beta1.7828
Data delayed at least 20 minutes, as of Feb 16 2026 11:48 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Oncoinvent ASA, formerly Bergenbio ASA, is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The Company is based in Bergen, Norway with a subsidiary in Oxford, UK.

  • Revenue in NOK (TTM)5.41m
  • Net income in NOK-107.58m
  • Incorporated2008
  • Employees7.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.